JP2015523072A5 - - Google Patents

Download PDF

Info

Publication number
JP2015523072A5
JP2015523072A5 JP2015520567A JP2015520567A JP2015523072A5 JP 2015523072 A5 JP2015523072 A5 JP 2015523072A5 JP 2015520567 A JP2015520567 A JP 2015520567A JP 2015520567 A JP2015520567 A JP 2015520567A JP 2015523072 A5 JP2015523072 A5 JP 2015523072A5
Authority
JP
Japan
Prior art keywords
composition
purified recombinant
seq
conversion
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523072A (ja
JP6171007B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/048561 external-priority patent/WO2014005014A2/en
Publication of JP2015523072A publication Critical patent/JP2015523072A/ja
Publication of JP2015523072A5 publication Critical patent/JP2015523072A5/ja
Application granted granted Critical
Publication of JP6171007B2 publication Critical patent/JP6171007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520567A 2012-06-29 2013-06-28 組換えイズロン酸2スルファターゼの精製 Active JP6171007B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
US61/666,733 2012-06-29
PCT/US2013/048561 WO2014005014A2 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016060910A Division JP6505629B2 (ja) 2012-06-29 2016-03-24 組換えイズロン酸2スルファターゼの精製

Publications (3)

Publication Number Publication Date
JP2015523072A JP2015523072A (ja) 2015-08-13
JP2015523072A5 true JP2015523072A5 (cg-RX-API-DMAC7.html) 2016-01-07
JP6171007B2 JP6171007B2 (ja) 2017-07-26

Family

ID=49778401

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015520567A Active JP6171007B2 (ja) 2012-06-29 2013-06-28 組換えイズロン酸2スルファターゼの精製
JP2016060910A Active JP6505629B2 (ja) 2012-06-29 2016-03-24 組換えイズロン酸2スルファターゼの精製
JP2018067404A Withdrawn JP2018121645A (ja) 2012-06-29 2018-03-30 組換えイズロン酸2スルファターゼの精製
JP2020037811A Active JP7594365B2 (ja) 2012-06-29 2020-03-05 組換えイズロン酸2スルファターゼの精製

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016060910A Active JP6505629B2 (ja) 2012-06-29 2016-03-24 組換えイズロン酸2スルファターゼの精製
JP2018067404A Withdrawn JP2018121645A (ja) 2012-06-29 2018-03-30 組換えイズロン酸2スルファターゼの精製
JP2020037811A Active JP7594365B2 (ja) 2012-06-29 2020-03-05 組換えイズロン酸2スルファターゼの精製

Country Status (39)

Country Link
US (7) US9051556B2 (cg-RX-API-DMAC7.html)
EP (2) EP3441398A1 (cg-RX-API-DMAC7.html)
JP (4) JP6171007B2 (cg-RX-API-DMAC7.html)
KR (5) KR101380740B1 (cg-RX-API-DMAC7.html)
CN (3) CN107596358A (cg-RX-API-DMAC7.html)
AR (1) AR091647A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013282395C1 (cg-RX-API-DMAC7.html)
BR (1) BR112014032567B1 (cg-RX-API-DMAC7.html)
CA (2) CA2877517C (cg-RX-API-DMAC7.html)
CL (1) CL2014003567A1 (cg-RX-API-DMAC7.html)
CO (1) CO7240396A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140588A (cg-RX-API-DMAC7.html)
CY (1) CY1121519T1 (cg-RX-API-DMAC7.html)
DK (1) DK2867245T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000294A (cg-RX-API-DMAC7.html)
EA (2) EA202090044A1 (cg-RX-API-DMAC7.html)
ES (1) ES2689468T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400303A (cg-RX-API-DMAC7.html)
HK (3) HK1209431A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20181897T1 (cg-RX-API-DMAC7.html)
HU (1) HUE040769T2 (cg-RX-API-DMAC7.html)
IL (4) IL236315A (cg-RX-API-DMAC7.html)
LT (1) LT2867245T (cg-RX-API-DMAC7.html)
MX (3) MX366906B (cg-RX-API-DMAC7.html)
MY (3) MY180287A (cg-RX-API-DMAC7.html)
NZ (3) NZ733366A (cg-RX-API-DMAC7.html)
PE (1) PE20150720A1 (cg-RX-API-DMAC7.html)
PH (3) PH12014502871A1 (cg-RX-API-DMAC7.html)
PL (1) PL2867245T3 (cg-RX-API-DMAC7.html)
PT (1) PT2867245T (cg-RX-API-DMAC7.html)
RS (1) RS58005B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201408761VA (cg-RX-API-DMAC7.html)
SI (1) SI2867245T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800612T1 (cg-RX-API-DMAC7.html)
TR (1) TR201815811T4 (cg-RX-API-DMAC7.html)
TW (2) TWI553120B (cg-RX-API-DMAC7.html)
UA (2) UA129561C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014005014A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201409397B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018122A2 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the cns
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CN109641971B (zh) 2016-08-25 2023-04-04 Jcr制药股份有限公司 抗体融合蛋白的制造方法
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3898689A1 (en) * 2018-12-20 2021-10-27 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
US20220098279A1 (en) * 2019-01-30 2022-03-31 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
JP2023546682A (ja) * 2020-10-23 2023-11-07 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼの製造中に総シアル酸含量(tsac)を制御する方法
CN117042791A (zh) 2021-02-12 2023-11-10 阿雷克森制药公司 碱性磷酸酶多肽及其使用方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
CA2185324A1 (en) 1994-03-16 1995-09-21 Steven D. Rosen Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
WO2000050443A2 (en) 1999-02-26 2000-08-31 Millennium Pharmaceutcals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
ATE348173T1 (de) 1999-04-26 2007-01-15 Genentech Inc Zellenzuchtverfahren für glycoproteine
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
WO2001060991A2 (en) 2000-02-17 2001-08-23 Incyte Genomics, Inc. Human kinases
CA2400638A1 (en) 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002098455A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
PL377731A1 (pl) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2−oスルファターゼ組成物および関連の方法
EP2325301B1 (en) 2003-02-11 2015-09-02 Shire Human Genetic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE)
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005073367A1 (en) 2004-01-30 2005-08-11 Zymenex A/S Production and purification of recombinant arylsulfatase a
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
SI2267024T1 (sl) 2005-06-03 2012-09-28 Ares Trading Sa Proizvodnja rekombinantnega IL-18 vezavnega proteina
CN101437839A (zh) 2006-03-20 2009-05-20 米德列斯公司 蛋白质纯化
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
US8128925B2 (en) * 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
JP6063380B2 (ja) * 2010-06-25 2017-01-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド サンフィリポ症候群b型の処置
SMT201900594T1 (it) 2010-06-25 2019-11-13 Shire Human Genetic Therapies Metodi e composizioni per il rilascio nell’snc di iduronato-2-solfatasi
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CN103153337A (zh) * 2010-09-28 2013-06-12 共立制药股份有限公司 黏膜佐剂组合物
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (ko) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 동적으로 튜닝 가능한 산란각을 갖는 산광기
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Similar Documents

Publication Publication Date Title
JP2015523072A5 (cg-RX-API-DMAC7.html)
AR091647A1 (es) Purificacion de iduronato-2-sulfatasa
TR201900128T4 (tr) Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller.
HRP20160490T4 (hr) Pripravak i oblik koji sadrže rekombinantnu humanu iduronat-2-sulfatazu te postupci njihove pripreme
BR112012033703A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
JP2007175057A5 (cg-RX-API-DMAC7.html)
BR112014007469A2 (pt) arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas
HRP20190982T1 (hr) Peptidi i njihova uporaba
WO2010057203A3 (en) Hdl particles for delivery of nucleic acids
MX2009002816A (es) Proteinas de fusion de albumina.
DK2343320T3 (da) Anti-gitr-antistoffer og anvendelser deraf
HK1206764A1 (en) Nutritive proteins and methods
BR112012033714A2 (pt) polipeptídeo com atividade de acetil xilano esterase e seus usos.
HK1206762A1 (en) Nutritive fragments and proteins with low or no phenylalanine and methods
WO2011097381A3 (en) Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
BR112015009201A2 (pt) composição compreendeendo um polipeptídeo recombinante, ácido nucleico codificando o mesmo, célula hospedeira, bem como métodos para produzir uma beta-glucosidase e para hidrolisar um substrato de biomassa lignocelulósica
JP2013503110A5 (cg-RX-API-DMAC7.html)
JP2015533791A5 (cg-RX-API-DMAC7.html)
HK1206763A1 (en) Charged nutritive fragments, proteins and methods
WO2013016724A3 (en) Decarboxylase proteins with high keto-isovalerate decarboxylase activity
JP2014510101A5 (cg-RX-API-DMAC7.html)
BR112014003841A2 (pt) estratégia de múltiplas cópias para produção em alto título e alta pureza de proteínas de múltiplas subunidades tal como anticorpos em micróbios transformados tal como pichia pastoris
HRP20161009T1 (hr) Modificirani omci kao inhibitor komplementa
TR201901259T4 (tr) Karaciğere özgü tanı için hidrofobik modifiye peptidler.
EP3263123A3 (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same